Retsina Meyer, Ph.D., serves as Head of Corporate Strategy at Delix Therapeutics, where she leads business development and strategic partnerships, fundraising, corporate and portfolio strategy, intellectual property, investor relations, and corporate communications. Her mission is to translate scientific breakthroughs into medicines that meaningfully improve patients’ lives. She brings extensive experience across life sciences company building, deal execution, and translational science, with a focus on advancing innovative therapeutic platforms into differentiated clinical products.
Prior to Delix, Dr. Meyer served as an Entrepreneur-in-Residence and strategic advisor to venture capital firms, startups, and academic founders, guiding company formation, translational strategy, and financing for deep-tech platforms. She was the Founder of Resilience Therapeutics, a biotechnology company advancing multiple precision medicine programs for neuropsychiatric disorders, and previously held strategic and business development leadership roles at CV Biosciences, where she directed translational science programs, led the innovation incubator, and drove partnerships supporting precision CNS initiatives.
Dr. Meyer earned her Ph.D. in Neuroscience from the Massachusetts Institute of Technology and was a Fulbright Scholar at the Norwegian University of Science and Technology. She holds bachelor’s degrees in Mathematics, Biochemistry and Molecular Biophysics, and Biopsychology from the University of Arizona.